Royal Philips, the parent company of Philips Healthcare, said it has formed a partnership with the University of Texas MD Anderson Cancer Center to better personalize oncology treatment for patients.
As a result of the collaboration, Philips' oncology informatics software will be used to connect oncologists and pathologists around the world to MD Anderson's Precision Oncology Decision Support (PODS) system. Physicians can then personalize therapy based on the patient's genomic profile, according to the vendor.
Designed as an evidence-based tool to facilitate therapeutic decision-making at the point of care, PODS provides actionable clinical information -- including approved therapies and available clinical trials -- based upon genetic alterations within the tumor, Philips said. The company's software then provides clinicians with a unified view of therapies and clinical trials in the context of their patient's unique tumor.
